Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Cutaneous Biology Research Center
149 13th Street, 3rd floor
Charlestown,
MA
02129
Phone: 617-724-8128
Email: sdemehri1@mgh.harvard.edu
The focus of the Demehri laboratory is to determine the role of the immune system in regulating the early stages of cancer development in order to harness its anti-tumor potential for cancer prevention and treatment. To date, several cancer immunotherapies have been developed with proven efficacy against late-stage cancers; however, the role of the immune system in preventing the early development of cancer remains uncertain. The research in the Demehri laboratory is focused on identifying the immune mechanisms that drive an immune activation sufficient to prevent cancer formation from pre-cancerous lesions. This approach raises a great opportunity to discover novel immune pathways that can be leveraged in cancer therapy and prevention.
To realize the potential of cancer immunoprevention, our laboratory studies the pathways that lead to immune system activation against early phases of malignant transformation. Devising a mechanism to activate the immune system against pre-cancers and early-stage cancers has clear preventive implications by directly blocking cancer development and recurrence. Our research aims to improve care for a large population of patients with hereditary cancer syndromes, exposure to carcinogens, pre-cancerous lesions, and early invasive cancers. In addition, our discoveries will have immunotherapeutic benefits by potentiating immunity against late disease.
To pursue this goal, our laboratory studies the role of alarmins, damage-associated molecular patterns (DAMPs)/stress signals, commensal viruses, carcinogens, and aging-associated factors in regulating early cancer development. The major areas of research in our laboratory are:
Postdoctoral Research Fellow position is available for a highly motivated individual with expertise in immunology, cancer biology and genomics. Expertise in biochemical, immunological and mice experimentations are required for this position.
Interested candidates should send their information including CV and the name of 2-3 references to Dr. Shawn Demehri: sdemehri1@mgh.harvard.edu
For the full list of publications from the Demehri lab, please visit PubMed here.
Schiferle, E. B., Cheon, S. Y., Ham, S., Son, H. G., Messerschmidt, J. L., Lawrence, D. P., Cohen, J. V., Flaherty, K. T., Moon, J. J., Lian, C. G., Sullivan, R. J., Demehri, S., Rejection of benign melanocytic nevi by nevus-resident CD4(+) T cells. Science Advances 7, (2021).
Li, K., Li, T., Feng, Z., Huang, M., Wei, L., Yan, Z., Long, M., Hu, Q., Wang, J., Liu, S., Sgroi, D. C., Demehri, S., CD8(+) T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Science Advances 7, (2021).
Park, J. H., Ameri, A. H., Dempsey, K. E., Conrad, D. N., Kem, M., Mino-Kenudson, M., Demehri, S., Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation. EMBO J 40, (2021).
Strickley JD, Messerschmidt JL, Awad ME, Li T, Hasegawa T, Ha DT, Nabeta HW, Bevins PA, Ngo KH, Asgari MM, Nazarian RM, Neel VA, Jenson AB, Joh J, and Demehri S. Immunity to commensal papillomaviruses protects against skin cancer. Nature. 2019 Nov;575(7783):519-522. PMID: 31666702.
Rosenberg AR, Tabacchi M, Ngo KH, Wallendorf M, Rosman IS, Cornelius LA, Demehri S. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight. 2019;4(6). Epub 2019/03/22. doi: 10.1172/jci.insight.125476.
Ameri AH, Moradi Tuchayi S, Zaalberg A, Park JH, Ngo KH, Li T, Lopez E, Colonna M, Lee RT, Mino-Kenudson M, Demehri S. IL-33/regulatory T cell axis triggers the development of a tumor-promoting immune environment in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2019. Epub 2019/01/31. doi: 10.1073/pnas.1815016116.
Cunningham, T.J., Tabacchi, M., Eliane, J.P., Tuchayi, S.M., Manivasagam, S., Mirzaalian, H., Turkoz, A., Kopan, R., Schaffer, A., Saavedra, A.P., Wallendorf, M., Cornelius, L.A., and Demehri, S. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 2017; 127(1): 106-116.
Demehri, S., Cunningham, T.J., Manivasagam, S., Ngo, K.H., Moradi Tuchayi, S., Reddy, R., Meyers, M.A., DeNardo, D.G., and Yokoyama, W.M. Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. J Clin Invest 2016; 126(4): 1458-70.
Demehri, S., Turkoz, A., Manivasagam, S., Yockey, L.J., Turkoz, M., and Kopan, R. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell 2012; 22(4): 494-505.
Shawn Demehri, M.D., Ph.D.Associate Professor
Massachusetts General Hospital
Harvard Medical School
B.S.: Biology, Washington State University
M.D.: Washington University in St. Louis
Ph.D.: Cell and Molecular Biology, Washington University in St. Louis
Residency: Dermatology, Barnes Jewish Hospital/ Washington University
Postdoctoral Fellowship: Immunology, Washington University in St. Louis
Marjan Azin, M.D.M.D.: Tehran University of Medical Sciences (TUMS), Iran
Marjan received her medical diploma from Tehran University of Medical Science in 2015. She has directed research projects at her hospital, studying the prognostic significance of Matrix Metalloproteinase-7 (MMP-7) in colorectal cancer survival, the effect of exercise program in serum Vaspin level in diabetic patients, and studying sleep disorders in patients with neuropathic pain. At Children Medical Center, she the immune dysregulation in children with allergic skin diseases. Marjan is studying the role of alarmins in suppressing cancer development in patients with breast cancer cutaneous metastasis in the Demehri lab.
Hiroshi Higuchi, Ph.D.B.S., M.S. & Ph.D.: Bioengineering, Nagoya University, Japan
Hiroshi received his Ph.D. in 2016 studying the role of sialic acid-binding lectin Siglecs in the inflammatory regulation in macrophages. He also worked on the analysis of macrophage function in the development of Epstein-Barr virus (EBV)-associated B-cell lymphoma as a Postdoctoral Fellow in Japan. In this study, he demonstrated the importance of extracellular vesicles as a novel communicator between tumor cells and macrophages. His current work in the Demehri Lab is focused on the innate immune function of epithelial cells in response to papillomavirus infection.
Jennet HojanazarovaB.S.: Biology, Waldorf University
Jennet has graduated from Waldorf University, Iowa with a B.S. in Biology. Jennet studied nonsyndromic orofacial clefts by measuring enhancer activity of disease-associated SNPs at the University of Iowa. She also measured the effects of IP3Rs and ALG-2 on the ER-to-Golgi transport at the University of Montana. In the Demehri lab, Jennet is studying the role of CD4+ T cells in regulating adenocarcinoma of the lung. She is also assisting in the study of commensal viruses to determine their impact on innate immunity.
Monica JaffeeMonica is a current undergraduate at Northeastern University pursuing a B.S. degree in Biological Sciences and a B.A. degree in Philosophy of Ethics. Her background includes lab work in biological contamination as well as in bacterial cell cultures. In the Demehri lab, Monica is studying the mechanism of NK cell effects in cancer immunology.
Emanuela Marchese, Ph.D.B.S.: Biotechnology for Health, University of Naples Federico II, Italy
M.S.: Biology, University of Naples Federico II, Italy
Ph.D.: Medical Clinical and Experimental Science, University of Campania “L.Vanvitelli”, Italy
Emanuela received her Ph.D. in 2021 studying kidney disease pathophysiology in Bardet-Biedl Syndrome. She has also been involved in several skin biology projects and has led efforts to develop proteomics- and metabolomics-based platforms. After completed her Ph.D. training, Emanuela was awarded the AICF’s postdoctoral fellowship to perform her training in the Demehri lab. Her current work is focused on the role of the immune system in regulating the early stages of cancer development in skin and breast cancer. In addition, she is studying the immunology of transition zones to determine the mechanisms of disease susceptibilities associated with these epithelial sites.
Mahsa Mortaja, M.D.M.D.: Tehran University of Medical Sciences (TUMS), Iran
Mahsa received her medical doctorate degree from Tehran University of Medical Science in 2018. After Graduation she has worked at Cancer Research Center of Iran, studying cancer immunology and pathology. Her previous research experience has been focused on understanding the role of the immune system in prevention of head and neck squamous cell carcinoma. She investigated the association between allergic disorders and risk of head and neck mucosal squamous cell carcinoma. In addition, she studied the role of cancer associated fibroblasts in tumor growth, invasion, survival and metastasis in oral squamous cell carcinoma. In the Demehri lab, Mahsa is studying the mechanism of chronic inflammation-induced cancer development.
Tomonori Oka, M.D., Ph.D.M.D.: University of Tokyo, Japan
Ph.D.: Dermatology, University of Tokyo, Japan
Tomonori received his Ph.D. degree in Dermatological sciences in 2018 studying the role of CXCL17 in psoriasis. During his clinical work as a dermatologist, he has focused on cutaneous T-cell lymphoma and atopic dermatitis. In the Demehri Lab, Tomonori is studying the mechanisms of skin cancer immunoprevention.
Jongho Park, Ph.D.B.Sc.: Computer Science Engineering and Biomedical Science, Pusan National University, Pusan, Korea
M.S. & Ph.D.: Biological Science, Seoul National University, Seoul, Korea
Jongho received his Ph.D. in biological science in 2016 studying protein modifications, such as ubiquitination and SUMOylation. He demonstrated a novel post-translational modification of tumor suppressor DBC1 and p53 induced by DNA damage, which can lead to upregulation of their suppressor activity. During his work in industry, Jongho has investigated the mechanism of rare genetic diseases, such as hemophilia, for the development of new therapeutic antibodies. His current work in the Demehri laboratory is focused on molecular signaling pathway within keratinocyte that can govern skin cancer immunity.
Quan PhamB.S.: Biochemistry and Molecular Biology, University of California, Irvine
M.S.: Immunology, Harvard Medical School (Degree in progress)
Quan is currently a master’s student at Harvard Medical School. He received his B.S. degree in Biochemistry and Molecular Biology from UC Irvine. After graduation, he joined the Melton lab at Harvard University, where he studied the role of the AKT/PI3K/mTOR pathway in pancreatic development and stem cell-derived beta-cell differentiation. In the Demehri lab, Quan is investigating the mechanism in which CD4+ T cells regulate breast cancer development. In the upcoming years, he hopes to pursue a PhD degree in cancer immunology.
Sabrina SmithB.S.: Nursing and Psychology, University of Miami
Post-Baccalaureate: University of Florida
Sabrina received her BSN, RN from the University of Miami in 2019 and completed the Pre-Health Post-Baccalaureate Program from the University of Florida in May 2021. Sabrina joined the Demehri Lab and is helping team members study the immunology of basal cell carcinoma (BCC). She is also helping to characterize the virome of immunocompetent and immunosuppressed individuals at high risk of developing squamous cell carcinoma (SCC).
Heehwa (Grace) Son, Ph.D.B.Sc.: Biotechnology, Konkuk University, Seoul, South Korea
M.S. & Ph.D.: Molecular biology and Genetics, Pohang University of Science and Technology (POSTECH), Pohang, South Korea
Heehwa received her PhD in molecular biology and genetics in 2018 studying the roles of RNA quality controls in aging process using a model organism, C. elegans. She found that one of the RNA quality control mechanisms, nonsense-mediated mRNA decay, has protective effects against aging. She also worked on investigating the roles of chaperones in lifespan regulation. In the Demehri lab, she is working on the cellular impacts of immunotherapies on early stage epithelial cancers.
Kathryn TrericeKatie is an undergraduate at Harvard College pursing a B.S. degree in Molecular and Cellular Biology. She is working with other lab members on their research projects while expanding both her knowledge of the field and her skills. Katie has joined our efforts to understand the role of CD4+ T cells in regulating lung cancer development.
Maulik Vyas, Ph.D.B.Sc. (Honors): Biomedical Science, University of Central Lancashire, UK
M.Sc.: Cancer Immunology & Biotechnology, University of Nottingham, UK
Ph.D.: Cancer Immunotherapy, University of Cologne, Germany
Maulik received his PhD in the field of Cancer Immunotherapy in 2016 where his work focused on designing and developing recombinant trispecific immunoligands (“triplebodies”) to harness NK cells against leukemia. His triplebodies showed successful retargeting of NKG2D-dependent NK cell response against primary leukemia cells in both, allogeneic and autologous settings. Significant in vivo potency of the triplebody was observed in immunodeficient (NSG) mouse model which further suggested its therapeutic potential. Maulik then worked as a postdoctoral fellow at Philipps University Marburg, Germany to study the NK cell suppression in response to soluble NKG2D-ligands or other yet unknown factors present within the ascites of ovarian cancer patients. His current work in the Demehri laboratory is focused on understanding how immune cells, in particular NK cells, regulate the early stages of cancer development.
Yun Xia, Ph.D.B.Sc. Biotechnology, Anhui normal University, China
M.Sc.: Immunology, Soochow University, China
Ph.D.: Immunology, Tsinghua University, China
Yun received his PhD degree in immunology from Tsinghua University in 2020. He found that mevalonate pathway inhibitors could induce strong immune responses and were suitable for vaccine adjuvants. The adjuvanticity associated with mevalonate pathway inhibition activates multiple arms of immunity, including Th1 and cytolytic T cell responses and is thus suitable for cancer immunotherapies. This discovery presented a new approach for the development of both vaccine and cancer research. In the Demehri lab, Yun focuses on studying the role of alarmins in COVID-19 response and the role of commensal viruses in immunity at epithelial sites.
Martina ZoiB.S. Biological Science (Degree in Progress), Northeastern University
B.S.: Medical Laboratories, University of West Attica, Athens, Greece
Martina joined Demehri lab as a student pursuing her Bachelor of Science degree in Biological science from Northeastern University. She has previously received a B.S. degree in Medical Laboratories at the University of West Attica. Though her background is in diagnostic laboratories, she hopes to gain research experience and advance her knowledge and skills to laboratory studies that will follow while assisting research fellows with their projects by conducting research experiments. She is interested in studying genetics and its role in breast cancer in its early development.
Demehri Lab Alumni
